Image For Activity Cover
2022 SAT7 New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data
Target Audience and Goal Statement
New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data

This activity is intended for cardiologists, primary care physicians, surgeons, nurses/nurse practitioners, and pharmacists.

 

The goal of this activity is for learners to be better able to improve knowledge of emerging cardiac myosin inhibitor therapy, the latest clinical data for cardiac myosin inhibitor therapies that target the underlying sarcomere dysfunction in HCM, and how to integrate this new evidence into clinical practice for appropriate patients.

 

Upon completion of this activity, participants will:

  • Identify sarcomere dysfunction as a therapeutic target in HCM
  • Analyze new data for the use of sarcomere-directed therapies to treat HCM
  • Differentiate emerging cardiac myosin inhibitors for the treatment of HCM
  • Identify patients who may benefit from novel cardiac myosin inhibition treatment strategies
See More at New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data
Summary
Cost: FREE
Credit Offered:
1.25 CME Credits
1.25 CNE Credits
1.25 CPE Credits
Recommended
Powered by Oasis.